Advertisement
Advertisement
U.S. markets open in 8 hours 29 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Immutep Limited (IMMP)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.1400-0.1000 (-4.46%)
At close: 04:00PM EDT
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • j
    jsedhu
    Insiders and other big institutions wanting to keep price down until they see fit.
  • E
    EQ
    This dropped to 2.05 now it’s on hold? Is this short squeeze?
  • g
    gert
    That volume
  • F
    Fernando
    Anyone as any explanation about this going down?
    Bullish
  • R
    Robin
    Annoying share price development. Could have seen it coming with the 10 times volume on the second of June and the buying before the knews in this stock. But anyway, results keep confirming and improving on what we already knew with even better percentages and higher amounts of patients. With the limited market cap, continuing good results and phase III coming for multiple indications I cannot imagine that the share price will stay this low. Patience is key I'm afraid.
  • g
    gert
    I know you can't compare but Cogent has good P2 results, up 90%. We also had good results, down 25%
  • g
    gert
    Does anyone know the extra announcement they told at ASCO?
  • P
    Patrick
    There is more coming. Wonder what the “announcement” will be? “Data from the trial will be presented in an Oral Presentation on 3 June 2022. Importantly, while the abstract contains data from the first 75 patients with a data cut off of January 2022, the Oral Presentation will present data from all 114 patients with a more recent data cut off and will be the subject of a further announcement
    from the Company.”
  • e
    edd
    This is the cheapest biotech stock available on the market ..!!!
    …(completely under the radar)…..!!!
    …..big pharma will buy it soon ( lag3 ) ..!!!
  • D
    Darren
    Price target just raised. from $4 to $8. This can be found on the company's website:

    Immutep Limited Buy
    Efti Was Out in Breast Cancer...Or Was it? Update from
    Ongoing SABCS meeting, Raising PT to $8
    Summary
    • The San Antonio Breast Cancer Symposium (SABCS) is ongoing and
    yesterday (12/9), there was significant activity in the space, including from
    Immutep, whose update on its P2b program in metastatic breast cancer (mBC)
    (efti + chemo vs. placebo + chemo) last night has resulted in IMMP shares up
    over 100% in the pre-market. So...wasn't efti essentially out of breast cancer
    following the miss on PFS back in March? Most thought so, including us, but
    not Immutep, nor did its China-based partner EOC Pharma (private).
    • The data around overall survival, particularly in pre-defined subgroups,
    suggests efti is having a meaningful and significant impact. The improvement
    in the ITT was 2.7 months but in patients under 65 years of age, which was
    2/3 of the efti-treated patients, that improvement rose to 7.1 months. In lowmonocyte count patients, the improvement was 9.4 months. There is more
    data to come in 1Q21 and concurrent with the SABCS data, EOC Pharma
    also announced it will start a new P2 efti trial in mBC in 1Q21 as well. IMMP
    conference call to discuss is today at 4:30pm ET (LINK).
    • Given the data in March, we had previously removed an indication for efti in
    mBC from our model. However, considering the SABCS update, EOC's activity
    and the continued demonstration of efti's potential and progression in lung
    and H&N cancers, we factor back in mBC into our model. We apply a 75% risk
    adjustment in mBC based on clinical trial risk, stage of development, and the
    prior data. Immutep is also well-capitalized with ~$38M in cash on the balance
    sheet. The net result is our PT increases to $8, from $4.
  • C
    Cured
    Sls will be launching on the 2 trial readouts this Quarter- $immp up 190% on weaker data UPDATE: Immutep shares soar 190% on positive results in trial of breast cancer treatment
    By Ciara Linnane
    Published: Dec. 10, 2020, 12:51 p.m. EDT
    Shares of Immumetp Ltd. (IMMP) an Australian biotech with a Nasdaq listing, soared 190% Thursday, after the company reported positive results from a trial of a treatment for metastatic breast cancer. The company said overall survival data from a Phase 2b study evaluating its lead product candidate eftilagimod alpha in combination with chemotherapy performed well compared with placebo and chemotherapy. The overall trend in OS in total population was a median survival benefit of plus 2.7 months. However, in patients under 65 years of age, the benefit was 7.1 months. The data were presented at the San Antonio Breast Cancer Symposium which is taking place this week. "Although the progression free survival data in the efti group did not show a significant improvement versus the comparator arm in AIPAC earlier this year, the OS data in general looks already very interesting and will mature further," AIPAC Principal Investigator, Hans Wildiers of University Hospital Leuven in Belgium said in a statement. "The OS data in subgroups such as those below age 65 years are highly encouraging and may lead to more effective treatment options for metastatic breast cancer patients." Maxim analyst Jason McCarthy raised his stock price target to $8 from $4 on the news. "The data around overall survival, particularly in pre-defined subgroups, suggests efti is having a meaningful and significant impact," McCarthy wrote in a note to clients. Maxim rates the stock a buy. Shares of Greenwich LifeSciences Inc. (GLSI) were up 45%, after gaining more than 2,000% on Wednesday, also on promising news for a breast cancer treatment. Immutep shares have gained 218% in the year to date, while the SPDR S&P Biotech ETF (XBI) has gained 48% and the S&P 500 (^GSPC) has gained 14%.
  • S
    Sherry
    SYDNEY, Australia, April 28, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, announces further positive interim data from its ongoing Phase II TACTI-002 study. The data relates to the data cut-off date of 20 March 2020 and shows improving efficacy results.

    The results are being presented today as a poster short talk audio presentation as part of the high-impact paper presentation program by TACTI-002 Principle Investigator, Dr Martin Forster of University College London Hospitals NHS Foundation at the American Association for Cancer Research (AACR) Virtual Annual Meeting.

    TACTI-002 is being conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA (known as “MSD” outside the United States and Canada). It is evaluating the combination of the Company’s lead product candidate eftilagimod alpha (“efti” or “IMP321”) with MSD’s KEYTRUDA® (pembrolizumab) in up to 109 patients with second line HNSCC or NSCLC in first and second line.

    Immutep CSO and CMO, Dr Frederic Triebel said: “These very positive results for stage 1 demonstrate the benefits for NSCLC patients in receiving efti in combination with pembrolizumab. 53% of patients are now responding and we expect PFS to be more than 9 months. These consolidated results, with more tumour responses being confirmed by a second CT-scan and a longer follow up, are remarkable given that usually only 20% of patients respond to pembrolizumab monotherapy, if not pre-selected for high PD-L1 expression. It is also encouraging to see that 33% of HNSCC patients are responding, almost double the proportion that respond to pembrolizumab monotherapy and that the median PFS hasn’t yet been reached for this group.”

    Immutep CEO, Marc Voigt stated: “Efti is showing remarkable results for patients with NSCLC and HNSCC. These are multi-billion-dollar markets, with NSCLC expected to reach US$33.9 billion and HNSCC US$2.8 billion by 2026 respectively1. As the treatment duration continues, we will update ORR and PFS, positioning the Company strongly to advance efti in these indications.”
  • g
    gert
    Really????
  • M
    Mat
    Immutep receives positive EMA scientific advice for
    further clinical development of efti in MBC including Phase III
    • Positive feedback for the general clinical development program including the planned registrational
    Phase III trial in metastatic breast cancer (MBC)
    • Other regulatory engagement ongoing, including with the US Food and Drug Administration (FDA)
    SYDNEY, AUSTRALIA – 29 October 2021
    Bullish
  • b
    bob
    Could it be, that Immutep has us Patent on the combination Therapie of lag3 and BMS opdivo ???

    If this is correct it would be Quite big?!

    Immutep (ASX:IMM) shares have risen six per cent to a three-week high after its lead drug candidate was granted a US patent and the world’s largest asset manager upped its stake in the Sydney immunotherapy company.

    The patent “combined preparations for the treatment of cancer or infection” covers Immutep’s eftilagimod alpha (“efti”) when combined with Merck’s “miracle” anti-cancer drug Keytruda or Bristol Myer Squibb’s Opdivo.
    Bullish
  • S
    Sherry
    SYDNEY, Australia, July 15, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”) announces the grant of patent no. 10,711,060 entitled “Antibody molecules to LAG-3 and uses thereof” by the United States Patent and Trade Mark Office.

    This new United States patent is directed to embodiments of LAG525, a humanised form of Immutep’s IMP701 antibody which is out-licensed to Novartis AG. In particular, the patent is directed to nucleic acid molecules that code for the LAG525 antibody, to expression vectors and host cells that comprise these nucleic acids, and to methods of producing the LAG525 antibody by culturing the host cells of the invention.

    The application was originally filed as a second divisional application and this grant follows the grant of the first divisional application, as announced in March 2018. The patent is co-owned by Novartis AG and Immutep S.A.S. and will expire on 26 March 2035 (including a 13 day patent term adjustment).
  • P
    Patrick
    Immutep will have 4 catalysts this year: Phase II interim data sometime in the first half of 2021, Phase IIb overall survival rate data by mid-2021, Phase I final data sometime in 2021 (unclear 1st or 2nd half) and Phase II interim efficacy data "later in 2021" (unclear 1st or 2nd half). Given that they are the leader in LAG3 tech, the institutional interest and the previous very promising phase results (100% response with some patients) there is potential for a very, very good year for this company. Anyone's feelings about the stock and how it wavers day to day is completely irrelevant.
  • P
    Patrick
    May 20th open is the day to watch. May 19th 5pm ET. abstracts are published on the ASCO site. What is in an abstract: The poster abstract is the most important part of your proposal. It is a summary of your research poster, and tells the reader what your problem, method, results, and conclusions are. Most abstracts are only 75 -- 250 words long. I really think with the current messages being sent by Immutep it will be good news. Companies can not release until the set date.
Advertisement
Advertisement